Australian Patients Can Now Access Endoca Medicinal Cannabis
Sydney, July 31, 2018 AEST (ABN Newswire) - The Hydroponics Company Limited (
ASX:THC) (HDRPF:OTCMKTS) (THC or the Company), Australia's leading medicinal cannabis company(see Note below) advises that THC's wholly owned subsidiary, Canndeo Limited, has released its first medicinal cannabis products, imported from the Company's European strategic alliance partner, Endoca. The products are available through the Medicinal Cannabis Medicines Portal (MCMP: mcmp.com.au) under the Approved Prescriber and Special Access Schemes.
Key Points
- Endoca Medicinal Cannabis, imported by the Company now available to patients through the Medicinal Cannabis Medicines Portal
- Products available include Endoca's CBD and unique CBD+CBDA formulations
- Immediate patient access through the Approved Prescriber and Special Access Schemes
- Company advancing medicinal cannabis strategy - imported product followed by domestic production using pharmaceuticals manufacturing facility and growing capability
Canndeo is a founding partner of MCMP, developed by Sinapse Pty Ltd, a leader in pharmaceutical IT systems, which provides a streamlined process for medicinal cannabis prescribing and dispensing between health professionals and manufacturers of medicinal cannabis.
MCMP ensures a continuity of care between patients, carers, and their existing health professionals.
Pharmacies and prescribers can use MCMP to access THC imported Endoca oil products in both CBD and Endoca's unique CBD+CBDA formulations. To assist pharmacies and prescribers, Canndeo and Sinapse have made available various clinical materials and information on MCMP to registered prescribers and pharmacies.
Chief Executive Officer, Ken Charteris commented:
"We are pleased to now be delivering high quality medicinal cannabis products to the Australian market through MCMP having leveraged our global commercial partnerships, including Endoca and Sinapse.
"Using MCMP reduces the administrative burden on prescribing doctors and pharmacies, which is currently a key challenge for the prescribing of medicinal cannabis in Australia. We look forward to seeing the first patients using product supplied by THC in the coming weeks.
"Bringing product to the Australian market is a key step in the execution of our medicinal cannabis strategy, with imported product to be followed by THC's domestic production taking advantage of our industry leading pharmaceuticals manufacturing facility and significant growing capacity."
Note: Assessment based on key peers (CAN, AC8) comparison matrix
About THC Global Group Limited
THC Global Group Limited (ASX:THC) (OTCMKTS:HDRPF) (FRA:9TH) operates under a 'Farm to Pharma' pharmaceutical model, now holding all three key cannabis licences being a Cannabis Research Licence, a Medicinal Cannabis Licence (Cultivation), and a Manufacture Licence through its domestic medicinal cannabis subsidiaries THC Pharma and Canndeo. THC Global has secured a significant cannabis growing capacity over multiple cultivation projects and owns a pharmaceuticals bio-manufacturing facility with attached testing and product development laboratory. THC Global is in prime position to commence medicinal cannabis production to service both domestic patients and the global export market. THC Global is active globally with operations in Australia, New Zealand, and Canada and partnerships across Europe, Asia, and the Middle East. In addition to its core Australian medicinal cannabis assets, THC Global has a significant Canadian presence – both in cannabis and in hydroponics equipment. THC Global's Canadian cannabis operation, Vertical Canna, holds property in Nova Scotia, Canada being developed into a large scale cannabis production site. THC Global's hydroponics equipment division, Crystal Mountain, is a revenue generating manufacturer, wholesaler, and retailer of hydroponic equipment and supplies.
| ||
|
